help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vertongen, P.
Right arrow Articles by Cauvin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vertongen, P.
Right arrow Articles by Cauvin, A.

Endocrinology, Vol 135, 1537-1542, Copyright © 1994 by Endocrine Society

ARTICLES

Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23

P Vertongen, E Ciccarelli, MC Woussen-Colle, P De Neef, P Robberecht and A Cauvin
Department of Biochemistry and Nutrition, Medical School, Universite Libre de Bruxelles, Belgium.

The expression of the messenger RNAs coding for glucagon-like peptide-I (GLP-I) receptor, VIP receptor, and pituitary adenylate cyclase- activating polypeptide (PACAP) receptor as well as the expression of the receptor proteins were demonstrated in the rat medullary carcinoma of thyroid cell line 6/23 by the following experiments: 1) RNA extraction, reverse transcriptase, and polymerase chain reaction with specific primers; 2) binding of the radiolabeled ligands [125I]GLP-I-(7- 36)-NH2, [125I]PACAP-(1-27), and [125I]VIP and inhibition by, respectively, unlabeled GLP-I-(7-36)-NH2, PACAP-(1-27), and VIP; and 3) study of adenylate cyclase activation by the peptides and selective inhibition of the VIP/PACAP response by the antagonist [D-Phe2]VIP. Besides the highly selective GLP-I receptor, PACAP receptors of types I and II were present on the cell line and coupled to adenylate cyclase. PACAP stimulated the adenylate cyclase through type I and II receptors, whereas VIP interacted with type II receptors only. Messenger RNA analysis indicated that at least three splice variants of the PACAP type I receptor may be expressed in 6/23 cells.


This article has been cited by other articles:


Home page
 JNMHome page
M. Korner, M. Stockli, B. Waser, and J. C. Reubi
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
J. Nucl. Med., May 1, 2007; 48(5): 736 - 743.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Lacroix, N. N'Diaye, J. Tremblay, and P. Hamet
Ectopic and Abnormal Hormone Receptors in Adrenal Cushing's Syndrome
Endocr. Rev., February 1, 2001; 22(1): 75 - 110.
[Abstract] [Full Text]

Home page
 Biol. Reprod.Home page
F. El-Gehani, M. Tena-Sempere, and I. Huhtaniemi
Evidence That Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Regulator of Fetal Rat Testicular Steroidogenesis
Biol Reprod, November 1, 2000; 63(5): 1482 - 1489.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions
Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. J. Kieffer and J. Francis Habener
The Glucagon-Like Peptides
Endocr. Rev., December 1, 1999; 20(6): 876 - 913.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society